Scientists Identify Hidden Alzheimer's Enzyme IDOL and Successfully Shut It Down

Alzheimer's disease research has taken a potentially significant step forward with the identification of a new therapeutic target: an enzyme called IDOL, found naturally in brain cells. Scientists at Indiana University School of Medicine believe blocking this enzyme could offer a fresh strategy for treating Alzheimer's, one that goes beyond simply slowing the disease's progression.

In laboratory experiments using two animal models of Alzheimer's, researchers deleted the IDOL gene from different brain cell types — neurons and microglia (the brain's immune cells). The most striking results came from neuronal deletion. Removing IDOL from neurons substantially reduced amyloid plaques, the sticky protein deposits that are a defining feature of Alzheimer's pathology. This was unexpected, as scientists initially anticipated microglia — the primary producers of IDOL — to drive the greatest plaque-clearing effect.

Beyond plaque reduction, deleting IDOL also lowered levels of apolipoprotein E (APOE), particularly relevant because the APOE4 variant is the single largest genetic risk factor for late-onset Alzheimer's. The study further revealed increased levels of receptors involved in regulating both APOE and amyloid, receptors that are critical for maintaining neuron-to-neuron communication and healthy lipid metabolism in the brain.

Previous related research suggests that activating a pathway connected to these receptors may help some individuals remain cognitively resilient even with significant plaque accumulation — a phenomenon of enormous clinical importance since most patients are diagnosed only after substantial damage has occurred.

From a drug development standpoint, enzymes like IDOL are considered attractive targets because their well-defined binding sites allow for precise, potentially low-side-effect drug design. While these findings are still preclinical and years from clinical application, the discovery adds a compelling new avenue to Alzheimer's research, especially as existing treatments remain limited in their ability to restore — rather than merely preserve — cognitive function.